CVRx Inc
NASDAQ:CVRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CVRx Inc
Other Non-Cash Items
CVRx Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CVRx Inc
NASDAQ:CVRX
|
Other Non-Cash Items
$11.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Non-Cash Items
$522m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other Non-Cash Items
$332.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
32%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Non-Cash Items
$586m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Non-Cash Items
$729m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
4%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Non-Cash Items
$730m
|
CAGR 3-Years
9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
What is CVRx Inc's Other Non-Cash Items?
Other Non-Cash Items
11.4m
USD
Based on the financial report for Dec 31, 2025, CVRx Inc's Other Non-Cash Items amounts to 11.4m USD.
What is CVRx Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
70%
Over the last year, the Other Non-Cash Items growth was -41%. The average annual Other Non-Cash Items growth rates for CVRx Inc have been 43% over the past three years , 70% over the past five years .
